Ultragenyx Pharmaceutical (RARE) Work In Process (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Work In Process data on file, last reported at $33.0 million in Q1 2026.

• Quarterly Work In Process rose 44.02% year-over-year to $33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.0 million (up 44.02% YoY) and the FY2025 annual result came in at $27.0 million, up 22.73% from the prior year.
• Work In Process grew to $33.0 million in Q1 2026 per RARE's latest filing, from $27.0 million in the prior quarter.
• Across five years, Work In Process topped out at $33.0 million in Q1 2026 and bottomed at $12.0 million in Q1 2022.
• The 5-year median for Work In Process is $19.8 million (2025), against an average of $20.9 million.
• The widest annual swing landed in 2022, when Work In Process jumped 76.75%; it then decreased 21.77% in 2025.
• Tracing RARE's Work In Process over 5 years: stood at $17.5 million in 2022, then rose by 7.85% to $18.9 million in 2023, then advanced by 16.66% to $22.0 million in 2024, then rose by 22.73% to $27.0 million in 2025, then rose by 22.22% to $33.0 million in 2026.
• Per Business Quant, the three latest RARE Work In Process figures stand at $33.0 million (Q1 2026), $27.0 million (Q4 2025), and $29.2 million (Q3 2025).

Peer Comparison